Special Issue

Advanced Use of Adenoviral Vectors in Cancer and Gene Therapy

Message from the Guest Editor

In recent decades, we have witnessed major improvements in the therapy of patients with early-stage tumor due to new chemotherapy treatments, refined radiotherapy, and advanced operative techniques. However, serious limitations in classical cancer therapy still exist, and there is a need for innovative therapeutic approaches. The promising potential of adenoviral vectors is witnessed by the fact that the first-in-class gene therapy product to treat head and neck cancer was adenovirus coding for p53 that entered the commercial market in 2004. Nevertheless, further improvements in vector development technologies are essential to avoid activation of the endogenous signal transduction pathways and production of cytokines due to antivector immune responses. This Special Issue aims to collect the latest advances and state of the art of adenoviral vectors used in cancer and gene therapy. This includes but is not limited to virotherapy, oncolytic vectors, cancer targeting, cancer immune therapy, cancer vaccines, and novel adenoviral vectors that can infect and transduce target cell or tissue with high specificity.

Guest Editor

Dr. Dragomira Majhen

Ruđer Bošković Institute, Division of molecular biology, 10 000 Zagreb, Croatia

Deadline for manuscript submissions

closed (20 January 2022)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/78680

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

